DOCSLIB.ORG

An Investigation Into the Role of Optineurin in Macrophage-Mediated Acute Antibacterial Response in Inflammatory Bowel Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
An Investigation Into the Role of Optineurin in Macrophage-Mediated Acute Antibacterial Response in Inflammatory Bowel Disease An investigation into the role of optineurin in macrophage-mediated acute antibacterial response in inflammatory bowel disease By Thean Soon Chew A thesis submitted to UCL for the degree of Doctor of Philosophy Division of Medicine 2015 1 I, Thean Soon Chew confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. 2 ex nihilo nihil fit 3 Abstract Crohn’s disease (CD) is now recognised to be due to defective host responses to bacteria in genetically susceptible individuals. Others in our research group previously found defective neutrophil recruitment, bacterial clearance and monocyte-derived macrophage (MDM) proinflammatory cytokine secretion in CD. To investigate the defective cytokine secretion, we performed transcriptomic analysis and identified reduced MDM optineurin (OPTN) expression in 10% CD patients. Here, I show that macrophages stimulated with E. coli, bacterial Toll-like and NOD-like receptor ligands upregulate OPTN, a Golgi complex protein that regulates vesicle transport. In vitro, Optn-/- bone marrow-derived macrophages (BMDM) stimulated with E. coli secrete significantly lower levels of proinflammatory TNF and IL6 cytokines, which is normalised to wildtype levels on addition of lysosomal function inhibitors. In vivo, Optn-/- mice develop a more severe Citrobacter colitis with greater mortality, an early defective neutrophil recruitment to the bowel and lower levels of serum proinflammatory cytokines. The Optn-/- mice also demonstrated a similar phenotype of defective neutrophil recruitment and lower serum proinflammatory cytokines in an E. coli-induced peritonitis. These results indicate that the low OPTN expression originally identified in CD macrophages has likely contributed to an attenuated antibacterial response, which potentially led to the development of bowel inflammation. 4 Table of Contents Table of Contents ......................................................................................... 5 Table of Figures ......................................................................................... 12 Table of Tables ........................................................................................... 21 Acknowledgements ................................................................................... 22 Statement of Collaborative Work .............................................................. 23 List of Abbreviations ................................................................................. 24 Chapter 1 Introduction........................................................................... 27 1.1 Diagnosis and natural history of inflammatory bowel disease 27 1.1.1 Natural history of Crohn’s disease ................................................. 27 1.1.2 Natural history of ulcerative colitis ................................................. 30 1.2 Epidemiology and burden of inflammatory bowel disease ...... 31 1.2.1 Healthcare cost of inflammatory bowel disease ............................. 31 1.2.2 Rising incidence and prevalence of IBD ........................................ 32 1.3 Environmental effects on IBD ..................................................... 33 1.3.1 Smoking ......................................................................................... 33 1.3.2 Diet ................................................................................................ 33 1.4 Treatment of inflammatory bowel disease ................................ 34 1.4.1 5-Aminosalicylates ......................................................................... 34 1.4.2 Corticosteroids ............................................................................... 35 1.4.3 Thiopurine analogues .................................................................... 35 1.4.4 Anti-TNF therapy ........................................................................... 36 1.5 Pathogenesis of Crohn’s disease .............................................. 36 1.5.1 Infectious aetiology ........................................................................ 36 1.5.2 Dysbiosis ....................................................................................... 38 1.6 Genetic factors in Crohn’s disease ............................................ 38 1.6.1 NOD2 ............................................................................................. 39 5 1.6.2 ATG16L1 ....................................................................................... 40 1.6.3 The missing heritability in CD ........................................................ 44 1.7 Innate immunity in the gastrointestinal tract ............................ 44 1.7.1 Macrophages and neutrophils in gut mucosa ................................ 45 1.7.2 Cytokine trafficking in macrophages .............................................. 48 1.7.3 The innate immune system and Crohn’s disease .......................... 51 1.8 Defective innate immunity in Crohn’s disease ......................... 51 1.9 Optineurin .................................................................................... 55 1.9.1 Optineurin structure and function ................................................... 55 1.9.2 Optineurin in vesicle trafficking ...................................................... 57 1.9.3 Optineurin and autophagy ............................................................. 59 1.9.4 Optineurin and the type I interferon response ................................ 60 1.9.5 Optineurin and disease .................................................................. 61 1.10 Outline of thesis........................................................................... 62 1.10.1 Summary of background information ............................................. 62 1.10.2 Summary of investigations and hypothesis .................................... 63 Chapter 2 Materials and Methods ......................................................... 65 2.1 CD patient and healthy control recruitment .............................. 65 2.2 gDNA extraction, OPTN sequencing and SNP genotyping. ..... 66 2.3 Optn-/- mouse generation and verification ................................. 66 2.3.1 Optn-/- mouse generation ............................................................... 66 2.3.2 Mouse husbandry .......................................................................... 66 2.3.3 Mouse genotyping ......................................................................... 66 2.3.4 Optn-/- mouse verification ............................................................... 67 2.3.5 Investigating the naïve Optn-/- phenotype ...................................... 68 2.4 Optn-/-Nod2-/- mouse generation ................................................. 71 2.4.1 Nod2-/- mice ................................................................................... 71 2.4.2 Optn-/-Nod2-/- mice ......................................................................... 71 6 2.5 Antibodies and stains ................................................................. 71 2.5.1 Antibodies used in immunoblots .................................................... 71 2.5.2 Antibodies used in confocal microscopy ........................................ 72 2.5.3 Antibodies used in flow cytometry ................................................. 72 2.5.4 Antibodies used in immunohistochemistry ..................................... 72 2.6 Reagents ...................................................................................... 73 2.6.1 Heat-killed E. coli (HkEc) stock ...................................................... 73 2.6.2 MTT cell viability assay reagents ................................................... 73 2.6.3 Buffers ........................................................................................... 74 2.6.4 Cell culture media .......................................................................... 75 2.6.5 Bacterial culture broth .................................................................... 76 2.6.6 Histology and microscopy reagents ............................................... 76 2.7 Cell culture and stimulation ........................................................ 78 2.7.1 Monocyte-derived macrophages (MDM) ........................................ 78 2.7.2 THP-1 cells .................................................................................... 79 2.7.3 Bone marrow-derived macrophages (BMDM) ............................... 80 2.7.4 Thioglycollate induced peritoneal macrophages (TiPM) ................ 81 2.8 Macrophage Expression Microarray .......................................... 82 2.9 Quantitative reverse transcription PCR (qRT-PCR) .................. 83 2.9.1 Cell preparation and conversion into cDNA ................................... 83 2.9.2 qRT-PCR protocol ......................................................................... 84 2.10 Immunoblot .................................................................................. 85 2.10.1 Whole cell lysate preparation ......................................................... 85 2.10.2 Semi-dry transfer ........................................................................... 86 2.11 Immunoprecipitation ................................................................... 87 2.12 Mass spectrometry ...................................................................... 87 2.13 Subcellular fractionation ............................................................
Load more

Recommended publications
  • Microarray Expression Profile Analysis of Long Non-Coding Rnas in Optineurin E50K Mutant Transgenic Mice
    MOLECULAR MEDICINE REPORTS 16: 1255-1261, 2017 Microarray expression profile analysis of long non-coding RNAs in optineurin E50K mutant transgenic mice YUANYUAN LI, LIN JIN, AIMENG DONG, XINRONG ZHOU and HUIPING YUAN Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China Received April 12, 2016; Accepted March 23, 2017 DOI: 10.3892/mmr.2017.6722 Abstract. The biological role of long non-coding RNAs this may be important in the pathogenesis of POAG caused by (lncRNAs) involves various cellular processes and leads to the OPTN (E50K) mutation. human diseases. Mutations in the optineurin (OPTN) gene, including E50K, which encodes an amino acid substitution, Introduction have been associated with primary open angle glaucoma (POAG). The present study was designed to identify lncRNAs Glaucoma is a neurodegenerative ocular disease, which is associated with OPTN (E50K) transgenic mice and investi- recognized worldwide as the key causal factor in irreversible gate its functions in the pathogenesis of POAG. The retinas blindness (1). The predominant form of glaucoma is primary from six OPTN (E50K) transgenic and wild-type mice were open-angle glaucoma (POAG). There are multiple genetic collected separately, and lncRNA expression profiling was factors, which are significant in the etiology of glaucoma. performed using microarray analysis. Based on Pearson's There are >20 genetic loci associated with POAG, however, correlation analysis, an lncRNA and mRNA co-expression only a few of these have been identified, including myocilin, network was constructed. Gene Ontology (GO) and Kyoto WD-repeat domain 36, optineurin (OPTN), and TANK-binding Encyclopedia of Genes and Genomes enrichment analysis of kinase-1 (2,3).
    [Show full text]
  • 1 Metabolic Dysfunction Is Restricted to the Sciatic Nerve in Experimental
    Page 1 of 255 Diabetes Metabolic dysfunction is restricted to the sciatic nerve in experimental diabetic neuropathy Oliver J. Freeman1,2, Richard D. Unwin2,3, Andrew W. Dowsey2,3, Paul Begley2,3, Sumia Ali1, Katherine A. Hollywood2,3, Nitin Rustogi2,3, Rasmus S. Petersen1, Warwick B. Dunn2,3†, Garth J.S. Cooper2,3,4,5* & Natalie J. Gardiner1* 1 Faculty of Life Sciences, University of Manchester, UK 2 Centre for Advanced Discovery and Experimental Therapeutics (CADET), Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, UK 3 Centre for Endocrinology and Diabetes, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, UK 4 School of Biological Sciences, University of Auckland, New Zealand 5 Department of Pharmacology, Medical Sciences Division, University of Oxford, UK † Present address: School of Biosciences, University of Birmingham, UK *Joint corresponding authors: Natalie J. Gardiner and Garth J.S. Cooper Email: [email protected]; [email protected] Address: University of Manchester, AV Hill Building, Oxford Road, Manchester, M13 9PT, United Kingdom Telephone: +44 161 275 5768; +44 161 701 0240 Word count: 4,490 Number of tables: 1, Number of figures: 6 Running title: Metabolic dysfunction in diabetic neuropathy 1 Diabetes Publish Ahead of Print, published online October 15, 2015 Diabetes Page 2 of 255 Abstract High glucose levels in the peripheral nervous system (PNS) have been implicated in the pathogenesis of diabetic neuropathy (DN). However our understanding of the molecular mechanisms which cause the marked distal pathology is incomplete. Here we performed a comprehensive, system-wide analysis of the PNS of a rodent model of DN.
    [Show full text]
  • Comparison of the Rome IV Criteria with the Rome III Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care
    This is a repository copy of Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/166989/ Version: Accepted Version Article: Black, CJ, Craig, O, Gracie, DJ et al. (1 more author) (2020) Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gut. ISSN 0017-5749 https://doi.org/10.1136/gutjnl-2020-322519 © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. This manuscript version is made available under the CC BY-NC 4.0 license https://creativecommons.org/licenses/by-nc/4.0/ Reuse This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new works must also acknowledge the authors and be non-commercial. You don’t have to license any derivative works on the same terms. More information and the full terms of the licence here: https://creativecommons.org/licenses/ Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Black et al. Page 1 of 38 Accepted for publication 3rd September 2020 TITLE PAGE Title: Comparison of the Rome IV Criteria with the Rome III Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care.
    [Show full text]
  • Spink2 Modulates Apoptotic Susceptibility and Is a Candidate Gene in the Rgcs1 QTL That Affects Retinal Ganglion Cell Death After Optic Nerve Damage
    Spink2 Modulates Apoptotic Susceptibility and Is a Candidate Gene in the Rgcs1 QTL That Affects Retinal Ganglion Cell Death after Optic Nerve Damage Joel A. Dietz1., Margaret E. Maes1., Shuang Huang2, Brian S. Yandell2, Cassandra L. Schlamp1, Angela D. Montgomery1, R. Rand Allingham3, Michael A. Hauser3, Robert W. Nickells1* 1 Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin, United States of America, 2 Department of Biostatistics, University of Wisconsin, Madison, Wisconsin, United States of America, 3 Center for Human Genetics, Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America Abstract The Rgcs1 quantitative trait locus, on mouse chromosome 5, influences susceptibility of retinal ganglion cells to acute damage of the optic nerve. Normally resistant mice (DBA/2J) congenic for the susceptible allele from BALB/cByJ mice exhibit susceptibility to ganglion cells, not only in acute optic nerve crush, but also to chronic inherited glaucoma that is characteristic of the DBA/2J strain as they age. SNP mapping of this QTL has narrowed the region of interest to 1 Mb. In this region, a single gene (Spink2) is the most likely candidate for this effect. Spink2 is expressed in retinal ganglion cells and is increased after optic nerve damage. This gene is also polymorphic between resistant and susceptible strains, containing a single conserved amino acid change (threonine to serine) and a 220 bp deletion in intron 1 that may quantitatively alter endogenous expression levels between strains. Overexpression of the different variants of Spink2 in D407 tissue culture cells also increases their susceptibility to the apoptosis-inducing agent staurosporine in a manner consistent with the differential susceptibility between the DBA/2J and BALB/cByJ strains.
    [Show full text]
  • Platform Abstracts
    American Society of Human Genetics 65th Annual Meeting October 6–10, 2015 Baltimore, MD PLATFORM ABSTRACTS Wednesday, October 7, 9:50-10:30am Abstract #’s Friday, October 9, 2:15-4:15 pm: Concurrent Platform Session D: 4. Featured Plenary Abstract Session I Hall F #1-#2 46. Hen’s Teeth? Rare Variants and Common Disease Ballroom I #195-#202 Wednesday, October 7, 2:30-4:30pm Concurrent Platform Session A: 47. The Zen of Gene and Variant 15. Update on Breast and Prostate Assessment Ballroom III #203-#210 Cancer Genetics Ballroom I #3-#10 48. New Genes and Mechanisms in 16. Switching on to Regulatory Variation Ballroom III #11-#18 Developmental Disorders and 17. Shedding Light into the Dark: From Intellectual Disabilities Room 307 #211-#218 Lung Disease to Autoimmune Disease Room 307 #19-#26 49. Statistical Genetics: Networks, 18. Addressing the Difficult Regions of Pathways, and Expression Room 309 #219-#226 the Genome Room 309 #27-#34 50. Going Platinum: Building a Better 19. Statistical Genetics: Complex Genome Room 316 #227-#234 Phenotypes, Complex Solutions Room 316 #35-#42 51. Cancer Genetic Mechanisms Room 318/321 #235-#242 20. Think Globally, Act Locally: Copy 52. Target Practice: Therapy for Genetic Hilton Hotel Number Variation Room 318/321 #43-#50 Diseases Ballroom 1 #243-#250 21. Recent Advances in the Genetic Basis 53. The Real World: Translating Hilton Hotel of Neuromuscular and Other Hilton Hotel Sequencing into the Clinic Ballroom 4 #251-#258 Neurodegenerative Phenotypes Ballroom 1 #51-#58 22. Neuropsychiatric Diseases of Hilton Hotel Friday, October 9, 4:30-6:30pm Concurrent Platform Session E: Childhood Ballroom 4 #59-#66 54.
    [Show full text]
  • Identification of Genomic Targets of Krüppel-Like Factor 9 in Mouse Hippocampal
    Identification of Genomic Targets of Krüppel-like Factor 9 in Mouse Hippocampal Neurons: Evidence for a role in modulating peripheral circadian clocks by Joseph R. Knoedler A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Neuroscience) in the University of Michigan 2016 Doctoral Committee: Professor Robert J. Denver, Chair Professor Daniel Goldman Professor Diane Robins Professor Audrey Seasholtz Associate Professor Bing Ye ©Joseph R. Knoedler All Rights Reserved 2016 To my parents, who never once questioned my decision to become the other kind of doctor, And to Lucy, who has pushed me to be a better person from day one. ii Acknowledgements I have a huge number of people to thank for having made it to this point, so in no particular order: -I would like to thank my adviser, Dr. Robert J. Denver, for his guidance, encouragement, and patience over the last seven years; his mentorship has been indispensable for my growth as a scientist -I would also like to thank my committee members, Drs. Audrey Seasholtz, Dan Goldman, Diane Robins and Bing Ye, for their constructive feedback and their willingness to meet in a frequently cold, windowless room across campus from where they work -I am hugely indebted to Pia Bagamasbad and Yasuhiro Kyono for teaching me almost everything I know about molecular biology and bioinformatics, and to Arasakumar Subramani for his tireless work during the home stretch to my dissertation -I am grateful for the Neuroscience Program leadership and staff, in particular
    [Show full text]
  • Genetic Testing Medical Policy – Genetics
    Genetic Testing Medical Policy – Genetics Please complete all appropriate questions fully. Suggested medical record documentation: • Current History & Physical • Progress Notes • Family Genetic History • Genetic Counseling Evaluation *Failure to include suggested medical record documentation may result in delay or possible denial of request. PATIENT INFORMATION Name: Member ID: Group ID: PROCEDURE INFORMATION Genetic Counseling performed: c Yes c No **Please check the requested analyte(s), identify number of units requested, and provide indication/rationale for testing. 81400 Molecular Pathology Level 1 Units _____ c ACADM (acyl-CoA dehydrogenase, C-4 to C-12 straight chain, MCAD) (e.g., medium chain acyl dehydrogenase deficiency), K304E variant _____ c ACE (angiotensin converting enzyme) (e.g., hereditary blood pressure regulation), insertion/deletion variant _____ c AGTR1 (angiotensin II receptor, type 1) (e.g., essential hypertension), 1166A>C variant _____ c BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (e.g., maple syrup urine disease, type 1A), Y438N variant _____ c CCR5 (chemokine C-C motif receptor 5) (e.g., HIV resistance), 32-bp deletion mutation/794 825del32 deletion _____ c CLRN1 (clarin 1) (e.g., Usher syndrome, type 3), N48K variant _____ c DPYD (dihydropyrimidine dehydrogenase) (e.g., 5-fluorouracil/5-FU and capecitabine drug metabolism), IVS14+1G>A variant _____ c F13B (coagulation factor XIII, B polypeptide) (e.g., hereditary hypercoagulability), V34L variant _____ c F2 (coagulation factor 2) (e.g.,
    [Show full text]
  • Editorial BURRILL BERNARD CROHN (1884-1983): the MAN
    ABCDDV/967 ABCD Arq Bras Cir Dig Editorial 2013;26(4):253-255 BURRILL BERNARD CROHN (1884-1983): THE MAN BEHIND THE DISEASE Burrill Bernard Crohn (1884-1983): o homem por trás da doença Fábio Guilherme M. C. de CAMPOS1 e Paulo Gustavo KOTZE2 1Colorectal Surgery Division, Gastroenterology Department. Hospital das Clínicas, University of São Paulo Medical School, Brazil; 2Colorectal Surgery Unit, Cajuru University Hospital, Catholic University of Paraná, Curitiba, PR, Brazil urrill Bernard Crohn was born in June 13th, my professional life as a student of constipation and 1884, in the city of New York. From a family diarrhea. Sometimes I could wish to have chosen ear, of jewish emigrants from Europe, Theodore nose and throat as a specialty rather than the tail end B 3 and Leah Crohn had 12 children, educated as Jewish of the human anatomy…” . orthodoxy, still spread over the generations5. Gastroenterologists existed much earlier than In New York, he attended City College (Class of gastroenterology was recognized, and defined as 1902) where his interest for the medical career was one of the internal medicine’s specialties. That was born. According to his own biography, he decided to what happened with Crohn, as most of the digestive follow the medical pathway because his father used to diseases wards were in held of surgeons at that time. have terrible digestion problems; so, he chose to help He was only recognized as a full member of the him by studying medicine. He received his medical American Gastroenterological Association (AGA) in degree at Columbia University’s College of Physicians 1917, mentored and helped by William J.
    [Show full text]
  • Moschonas NK (2000) Craniosynostosis and Related Limb Anomalies
    Chromosome 10 Mouse Genome Informatics (MGI 2.8). This site is a comprehensive SNP Consortium. This is the website of the SNP Consortium Ltd, a listing of mammalian homology and comparative maps that public/private collaboration that has to date discovered and allows you to search by gene name or map location, as well as characterized nearly 1.8 million SNPs view whole-genome maps http://snp.cshl.org http://www.informatics.jax.org/menus/homology_menu.shtml UCSC Genome Bioinformatics. The UCSC Genome Bioinformatics National Center for Biotechnology Information (NCBI) dbSNP. site contains working drafts for the human genome and the This site is the single nucleotide polymorphism database main- mouse genome. The Genome Browser and the data it displays are tained by the National Center for Biotechnology Information freely available for academic, nonpro®t and personal use http://www.ncbi.nlm.nih.gov/SNP/ http://genome.ucsc.edu Sanger Centre. This site is the human chromosome 9 sequencing Washington University Genome Center. The focus of the project overview page that reports the sequencing status of the Washington University Genome Center is sequencing human chromosome. The Sanger Centre is a genome research institute and microbial genomes and analysis of genetic variations among funded by the Wellcome Trust populations. This site describes the various sequencing projects http://www.sanger.ac.uk/HGP/Chr9/ and provides progress updates http://www.genome.washington.edu/UWGC/ Chromosome 10 Intermediate article Nicholas K Moschonas, University of Crete and Institute of Molecular Biology and Article contents Biotechnology (IMBB-FORTH), Crete, Greece Human Chromosome Characteristics Chromosome 10 is a medium sized submetacentric chromosome corresponding to about Structure and Statistics of Chromosome 10 Genetic Map and Polymorphisms 4.2% of the genetic material in the genome.
    [Show full text]
  • Interacting Protein Kinase 1 (RIPK1) As a Therapeutic Target
    REVIEWS Receptor- interacting protein kinase 1 (RIPK1) as a therapeutic target Lauren Mifflin 1, Dimitry Ofengeim2 and Junying Yuan 1 ✉ Abstract | Receptor-interacting serine/threonine- protein kinase 1 (RIPK1) is a key mediator of cell death and inflammation. The unique hydrophobic pocket in the allosteric regulatory domain of RIPK1 has enabled the development of highly selective small-molecule inhibitors of its kinase activity, which have demonstrated safety in preclinical models and clinical trials. Potential applications of these RIPK1 inhibitors for the treatment of monogenic and polygenic autoimmune, inflammatory, neurodegenerative, ischaemic and acute conditions, such as sepsis, are emerging. This article reviews RIPK1 biology and disease- associated mutations in RIPK1 signalling pathways, highlighting clinical trials of RIPK1 inhibitors and potential strategies to mitigate development challenges. NF-κ B Receptor-interacting serine/threonine-protein kinase 1 peripherally restricted GSK′772 is being developed for (Nuclear factor κ light chain (RIPK1) is a master regulator of the cellular decision peripheral autoimmune diseases, including psoriasis, enhancer of activated B cells). between pro- survival NF- κB signalling and death in rheumatoid arthritis (RA) and ulcerative colitis12–14. A protein complex whose response to a broad set of inflammatory and pro-death The brain- penetrant DNL747 is in human clinical trial pathway, which can be 1,2 15,16 activated in response to stimuli in human diseases . RIPK1 kinase activation phase Ib/IIa for amyotrophic lateral sclerosis (ALS) . cytokines, free radicals, viral or has been demonstrated in post- mortem human patho- These trials have laid the groundwork for advancing bacterial antigens and other logical samples of autoimmune and neurodegenerative clinical applications of RIPK1 inhibitors.
    [Show full text]
  • Cardiac Atrial Compartmentalisation Proteomics: a Modified Density 2 Gradient Method to Analyse Endo-Lysosomal Proteins
    bioRxiv preprint doi: https://doi.org/10.1101/2021.02.22.432193; this version posted February 22, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Cardiac Atrial Compartmentalisation Proteomics: A Modified Density 2 Gradient Method to Analyse Endo-lysosomal Proteins 3 Thamali Ayagama1*, Samuel J Bose1*, Rebecca A Capel1*, David A Priestman1, Georgina 4 Berridge2, Roman Fisher2, Antony Galione1, Frances M Platt1, Holger Kramer3, Rebecca A B 5 Burton1# 6 7 1. University of Oxford, Department of Pharmacology, OX1 3QT Oxford, United Kingdom 8 2. Target Discovery Institute, University of Oxford, OX3 7FZ Oxford, United Kingdom 9 3. Biological Mass Spectrometry and Proteomics Facility, MRC London Institute of Medical 10 Sciences, Imperial College London, W12 0NN London, United Kingdom. 11 *Joint first authors; #corresponding author 12 Lead contact: [email protected] 13 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.02.22.432193; this version posted February 22, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 14 Summary 15 16 The importance of lysosomes in cardiac physiology and pathology are well 17 established, and evidence for roles in calcium signalling are emerging. We describe a 18 label-free proteomics method suitable for small cardiac tissue biopsies based on 19 density-separated fractionation, which allows study of endo-lysosomal (EL) proteins. 20 21 Density gradient fractions corresponding to tissue lysate; sarcoplasmic reticulum (SR), 22 mitochondria (Mito) (1.3 g/ml ); and EL with negligible contamination from SR or Mito 23 (1.04 g/ml), were analysed using Western Blot, enzyme activity assay and LC-MS/MS 24 analysis (adapted discontinuous Percoll, and sucrose differential density gradient).
    [Show full text]
  • Induction of Therapeutic Tissue Tolerance Foxp3 Expression Is
    Downloaded from http://www.jimmunol.org/ by guest on October 2, 2021 is online at: average * The Journal of Immunology , 13 of which you can access for free at: 2012; 189:3947-3956; Prepublished online 17 from submission to initial decision 4 weeks from acceptance to publication September 2012; doi: 10.4049/jimmunol.1200449 http://www.jimmunol.org/content/189/8/3947 Foxp3 Expression Is Required for the Induction of Therapeutic Tissue Tolerance Frederico S. Regateiro, Ye Chen, Adrian R. Kendal, Robert Hilbrands, Elizabeth Adams, Stephen P. Cobbold, Jianbo Ma, Kristian G. Andersen, Alexander G. Betz, Mindy Zhang, Shruti Madhiwalla, Bruce Roberts, Herman Waldmann, Kathleen F. Nolan and Duncan Howie J Immunol cites 35 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription http://www.jimmunol.org/content/suppl/2012/09/17/jimmunol.120044 9.DC1 This article http://www.jimmunol.org/content/189/8/3947.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of October 2, 2021.
    [Show full text]